Recently, phase I clinical trials were conducted in individuals with metastatic ER− breast cancer using the dual PI3Kα/γ and mTOR inhibitor, gedatolisib, in combination with cofetuzumab pelidotin, an antibody–drug conjugate with an auristatin payload targeting the Wnt co-receptor, protein tyrosine kinase 7 (PTK7) [113]. The gene discussed is MTOR; the disease is breast carcinoma.